Elanco Animal Health Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elanco Animal Health Incorporated on June 25, 2025. The report details a material definitive agreement regarding the company's accounts receivable securitization facility.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or total debt. The primary financial disclosure relates to the extension of the term for the Receivables Securitization Facility.
Material Changes
On June 25, 2025, Elanco entered into a First Amendment to its Receivables Loan Agreement with Coöperatieve Rabobank U.A., New York Branch, as Administrative Agent. Key changes include:
- Term Extension: The maturity date of the agreement was extended from August 3, 2026, to June 26, 2028.
- Parties Involved: Elanco Animal Health Incorporated (performance guarantor), Elanco SPEAR LLC (Borrower), and Elanco US Inc. (servicer).
- Other Amendments: The agreement includes amendments to certain other covenants and terms, though specific details are not disclosed in the summary.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the summary is subject to the full text of the agreement filed as Exhibit 10.1. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Review Exhibit 10.1 (First Amendment to Receivables Loan Agreement) for specific details on amended covenants and terms.
- Verify the impact of the extended maturity date (June 26, 2028) on the company's liquidity planning and debt maturity profile.
- Confirm the current utilization levels of the Receivables Securitization Facility in the most recent quarterly or annual report.